AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q112017

Application No.: 10/519,855

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1-7. (canceled).

8. (currently amended): A human IgM monoclonal antibody which induces

apoptosis of specifically recognizing HIV-infected cells upon binding to said cells, wherein and

including apoptosis of the infected cells, said antibody denominated 2G9 antibody obtainable by

a cell strain with an accession No.FERM BP-8378, and said antibody comprises a heavy-chain

eomprising sequence a H-chain-variable region encoded by a polynucleotide comprising the

nucleotide sequence of the base sequence SEQ ID No.1 SEQ ID NO: 1 and a light-chain variable

region encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 2L-

chain variable region encoded by the base sequence SEQ ID No.2.

9. (currently amended): A composition comprising the antibody of Claim 8 or 11

and a pharmaceutically acceptable carrier human IgM monoclonal antibody according to Claim 8

for the treatment of HIV infection, comprising the monoclonal antibody as an effective

ingredient.

10. (canceled).

7

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q112017

Application No.: 10/519,855

11. (currently amended): The antibody of Claim 8, wherein said antibody is produced by the hybridoma deposited under Accession No. A human IgM monoclonal antibody according to Claim 8 including a cell strain with an accession No. FERM BP-8378 for producing human IgM monoclonal antibody reacting with the HIV-infected cells.

12. (new): A method for treating HIV or AIDS in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the antibody of Claim 8 or 11.